[Therapeutic management of antiphospholipid antibody syndrome in pregnancy].
The antiphospholipid syndrome, recently described, associates thromboembolism risks, fetal losses and thrombopenia. An obstetrical survey of this syndrome implies previous analyses of maternal and fetal risks and leads to treatment which may associate low doses of aspirin, heparin, corticoids. This complex syndrome offers the best example of materno-fetal medicine usefulness.
Edelman
P
P
Service de Gynécologie Obstétrique, Hôpital Bichat, Paris.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D001241:Aspirin / Q000627:therapeutic use; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D011256:Pregnancy Outcome; D012307:Risk Factors; D013921:Thrombocytopenia / Q000209:etiology; D013923:Thromboembolism / Q000209:etiology
D000305:Adrenal Cortex Hormones; D006493:Heparin; D001241:Aspirin
Prise en charge thérapeutique du syndrome des anticorps antiphospholipides pendant la grossesse.